BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21558968)

  • 1. High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy.
    Buzaid AC; Schmerling RA; Vieira Guedes RA; de Freitas D; William WN
    Melanoma Res; 2011 Aug; 21(4):370-5. PubMed ID: 21558968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
    J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
    Powell S; Dudek AZ
    Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
    Tarhini AA; Kirkwood JM; Gooding WE; Cai C; Agarwala SS
    J Clin Oncol; 2007 Sep; 25(25):3802-7. PubMed ID: 17761969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
    J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
    Legha SS; Ring S; Eton O; Bedikian A; Plager C; Papadopoulos N
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
    J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
    O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G
    Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
    Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB
    Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
    Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma.
    Legha SS; Gianan MA; Plager C; Eton OE; Papadopoulous NE
    Cancer; 1996 Jan; 77(1):89-96. PubMed ID: 8630945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
    Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
    Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
    Kammula US; White DE; Rosenberg SA
    Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients' perceptions of fatigue in response to biochemotherapy for metastatic melanoma: a preliminary study.
    Fu MR; Anderson CM; McDaniel R; Armer J
    Oncol Nurs Forum; 2002 Jul; 29(6):961-6. PubMed ID: 12096293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
    Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
    J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
    Neri B; Vannozzi L; Fulignati C; Pantaleo P; Pantalone D; Paoletti C; Perfetto F; Turrini M; Mazzanti R
    Cancer Invest; 2006; 24(5):474-8. PubMed ID: 16939954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study.
    Mouawad R; Rixe O; Meric JB; Khayat D; Soubrane C
    Cytokines Cell Mol Ther; 2002; 7(4):151-6. PubMed ID: 14660055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.